Beranda › Kanker Payudara › Alabama
Uji klinis Kanker Payudara di Alabama
29 studi untuk Kanker Payudara mencari peserta di lokasi di Alabama.
Kota di Alabama
Teks studi resmi (Bahasa Inggris)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 2
Usia 60 ke atas · Wanita · Diperbarui 30 Sep 2026 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
Menerima peserta
Usia 18 hingga 90 · Wanita · Diperbarui 25 Sep 2026 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 22 Sep 2026 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
Menerima pesertaSukarelawan sehat diterima
Usia 30 hingga 74 · Wanita · Diperbarui 21 Sep 2026 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
Menerima pesertaStudi observasional
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
Menerima pesertaSukarelawan sehat diterima
Usia 45 hingga 74 · Wanita · Diperbarui 31 Jul 2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
Menerima pesertaFase 1
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Mei 2026 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Apr 2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
Menerima pesertaFase 3
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Feb 2026 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
Menerima pesertaFase awal 1
Usia 18 ke atas · Wanita · Diperbarui 26 Jan 2026 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Des 2025 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 31 Okt 2025 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.